Beam Therapeutics announced that Gopi Shanker, Ph.D., has been appointed as chief scientific officer. Dr. Shanker is a scientific leader with more than 20 years of drug development experience as well as experience with novel genetic medicine modalities. Dr. Shanker will report to Giuseppe Ciaramella, Ph.D., president of Beam, who has broad oversight of Beam’s research, manufacturing, regulatory, quality and pharmaceutical sciences organizations.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BEAM:
- Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer
- Beam Therapeutics initiated with a Market Perform at Bernstein
- Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference
- Stifel says SVB fallout ‘appears limited’ across firm’s biotech coverage
- Beam Therapeutics price target lowered to $105 from $125 at Wells Fargo
